9H-fluoren-9-ylmethyl N-[2-(ethylamino)-2-oxoethyl]carbamate

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 9H-fluoren-9-ylmethyl N-[2-(ethylamino)-2-oxoethyl]carbamate
• 化学式: C₁₉H₂₀N₂O₃
• 分子量: 324.4
• InChiKey: CKHQVDDIWGMWHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• PEPTIDE / PROTEIN IDENTIFICATION USING PHOTOREACTIVE CARRIERS FOR THE IMMOBILISATION OF THE LIGANDS
  申请人：Dilly Suzanne Jane

  公开号：US20100173793A1

  公开（公告）日：2010-07-08

  The invention provides a method of identifying a peptide or protein capable of binding a ligand which comprises: (i) providing a support, the support comprising a photoreactive group; (ii) reacting the photoreactive group with a ligand to attach the ligand to the support and produce a supported ligand; (iii) providing an expression library comprising a plurality of members, each member expressing a different peptide or protein; (iv) screening the expression library to identify one or more peptides or proteins which bind to the ligand; (v) isolating the member or each member of the library which expresses a peptide or protein which binds to the ligand; and (vi) identifying the peptide or protein which binds to the ligand. Supported photo-reactive compounds are disclosed comprising a photo-reactive group attached to a support via a spacer and a dendritic group, the dendritic group comprising attached thereto, optionally via a spacer, at least one further photo-reactive group and/or a second functional group. Compounds comprising photo-reactive groups attached to a support and a protein resistant group attached to the support are also provided, together with kits for carrying out the method of the invention.

  该发明提供了一种识别能够结合配体的肽或蛋白质的方法，包括：(i)提供一种支持物，该支持物包括一个光反应性基团；(ii)将光反应性基团与配体反应，将配体附着到支持物上并产生支持的配体；(iii)提供一个表达文库，该文库包含多个成员，每个成员表达不同的肽或蛋白质；(iv)筛选表达文库，以识别结合配体的一个或多个肽或蛋白质；(v)分离表达文库的每个成员，该成员表达结合配体的肽或蛋白质；(vi)识别结合配体的肽或蛋白质。还公开了支持光反应性化合物，其包括通过间隔物和树状基团将光反应性基团附着到支持物上，该树状基团包括通过间隔物连接至其上的至少一个进一步的光反应性基团和/或第二功能基团。还提供了附着于支持物上的光反应性基团和蛋白质抗性基团的化合物，以及用于执行该发明方法的试剂盒。
• Aryl-cyanoguanidine compounds
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US10023539B2

  公开（公告）日：2018-07-17

  The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2, R3, R4, R5, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumor disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.

  本发明涉及蛋白-赖氨酸N-甲基转移酶SMYD2（含SET和MYND结构域的蛋白2）抑制剂，特别是通式（I）的SMYD2-抑制性取代氰胍-吡唑啉类，其中R1、R2、R3、R4、R5、X和r具有本文所述和定义的含义；本发明还涉及包含根据本发明的化合物的药物组合物，以及它们对过度增殖性疾病，特别是癌症、肿瘤疾病的预防和治疗用途。本发明还涉及 SMYD2 抑制剂在良性增生性疾病、动脉粥样硬化性疾病、败血症、自身免疫性疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化性疾病和控制男性生育能力方面的用途。
• NOVEL ARYL-CYANOGUANIDINE COMPOUNDS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20170342034A1

  公开（公告）日：2017-11-30

  The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.